Last week, Protavio had the privilege of attending the Olink User Group Meeting 2024, held in Barcelona, where Olink experts gathered to share insights on the latest advancements in proteomics and biomarker research.
At the event, we presented our latest poster, which highlights an innovative automated platform for protein biomarker discovery, incorporating Olink Explore, automation and advanced bioinformatics. In our lab, this automated system demonstrated its strong performance and reliability, excelling across the key metrics of the Olink Concordance Test, including detectability, coefficient of variance, and correlation.
Furthermore, we presented findings from a feasibility study conducted within the framework of the DIOPTRA project, funded by the EU’s Mission on Cancer initiative (Grant Agreement #101096649). This study assessed the platform’s potential in early colorectal cancer (CRC) detection. Through the analysis of plasma samples from study participants —including CRC patients, individuals with advanced adenomas, and those with clear colonoscopy results—we discovered significant variations in protein expression. These findings prove the feasibility of the protein biomarker discovery pipeline developed in the DIOPTRA project.
The Olink User Group Meeting provided a dynamic and engaging environment for in-depth discussions on cutting-edge technologies and novel approaches in biomarker discovery and validation. As always, we were thrilled to connect with like-minded professionals who are just as passionate about advancing the science of proteomics as we are.
We would like to extend our sincere thanks to Olink for organizing such an insightful event and to all the attendees for their valuable insights and inspiring discussions. Protavio remains committed to continuing collaborations and pioneering breakthroughs in the world of proteomics and biomarker discovery.
With much more to come, we look forward to sharing more exciting developments and advancements in early cancer detection and beyond.